Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.
暂无分享,去创建一个
[1] R. Wolff,et al. Safety of inhaled proteins for therapeutic use. , 1998, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[2] V. Roggli,et al. Immunohistologic quantification of Pseudomonas aeruginosa in the tracheobronchial tree from patients with cystic fibrosis. , 1995, Pediatric pathology & laboratory medicine : journal of the Society for Pediatric Pathology, affiliated with the International Paediatric Pathology Association.
[3] G. K. Adams,et al. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. , 1993, JAMA.
[4] J. Mauderly,et al. Deposition and Clearance of Radiolabeled Particles from Small Ciliated Airways in Beagle Dogs , 1989 .
[5] M. Decramer,et al. Regulation of mucociliary clearance in health and disease. , 1999, The European respiratory journal.
[6] P. Bye,et al. Mucociliary clearance in cystic fibrosis , 2002, Pediatric pulmonology.
[7] J. Lewis,et al. Respiratory tract uptake of inhalants and metabolism of xenobiotics. , 1993, Annual review of pharmacology and toxicology.
[8] A. Ryrfeldt. The Bronchial Circulation—A Significant Local Distribution System in the Lung, in Inhalation Therapy? , 1990 .
[9] J. Patton,et al. Drug delivery via the respiratory tract. , 1994, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[10] C. Garrard,et al. Theoretic analysis of sites of aerosol deposition in the human lung. , 1981, Chest.
[11] M. Newhouse,et al. Aerosol penetration into the lung; influence on airway responses. , 1981, Chest.
[12] T. Isawa,et al. Mucociliary clearance and transport in bronchiectasis: global and regional assessment. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] A. Yamamoto,et al. Absorption Enhancement of Intrapulmonary Administered Insulin by Various Absorption Enhancers and Protease Inhibitors in Rats , 1994, The Journal of pharmacy and pharmacology.
[14] R. Perry,et al. Interpretation of "24 Hour Lung Retention" in Studies of Mucociliary Clearance , 1988 .
[15] U. Klotz,et al. Extrahepatic Metabolism of Drugs in Humans , 1994, Clinical pharmacokinetics.
[16] M. Newhouse,et al. Effect of chest physiotherapy on the removal of mucus in patients with cystic fibrosis. , 2015, The American review of respiratory disease.
[17] J. Crapo,et al. Allometric relationships of cell numbers and size in the mammalian lung. , 1992, American journal of respiratory cell and molecular biology.
[18] C. P. Yu,et al. Theoretical Lung Deposition of Hygroscopic NaCl Aerosols , 1985 .
[19] S. Clarke,et al. Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition. , 1989, Chest.
[20] J. Forrest,et al. Nasal ciliary ultrastructure and function in patients with primary ciliary dyskinesia compared with that in normal subjects and in subjects with various respiratory diseases. , 1984, The American review of respiratory disease.
[21] J. Lammers,et al. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. , 1996, Thorax.
[22] Q A Summers,et al. Inhaled drugs and the lung , 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[23] S. Anderson,et al. Regional deposition of saline aerosols of different tonicities in normal and asthmatic subjects. , 1994, The European respiratory journal.
[24] M. Newhouse,et al. The effects of preferential deposition of histamine in the human airway. , 2015, The American review of respiratory disease.
[25] W. Kreyling,et al. Comparison of experimental and calculated data for the total and regional deposition in the human lung , 1985 .
[26] T. Clark,et al. The importance of particle size in response to inhaled bronchodilators. , 1982, European journal of respiratory diseases. Supplement.
[27] B. Karlberg,et al. Intrapulmonary administration of insulin to healthy volunteers , 1996, Journal of internal medicine.
[28] R. Loddenkemper,et al. Patterns of distribution and clearance of aerosols in patients with bronchiectasis. , 2015, The American review of respiratory disease.
[29] J. Ilowite,et al. Regional deposition of aerosolized pentamidine. Effects of body position and breathing pattern. , 1990, Annals of internal medicine.
[30] H. Wagner,et al. The effect of bronchial obstruction on central airway deposition of a saline aerosol in patients with asthma. , 1986, The American review of respiratory disease.
[31] P. Barnes,et al. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. , 1990, The American review of respiratory disease.
[32] A. James,et al. The distribution of eosinophils and lymphocytes in the large and small airways of asthmatics. , 1997, The European respiratory journal.
[33] M. Dolovich. New propellant-free technologies under investigation. , 1999, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[34] J. Markham,et al. Pulmonary deposition of aerosols in children with cystic fibrosis. , 1974, The Journal of pediatrics.
[35] H S Shannon,et al. Effect of lung function and mode of inhalation on penetration of aerosol into the human lung. , 1977, Thorax.
[36] L. Heinemann,et al. Time–action Profile of Inhaled Insulin , 1997, Diabetic medicine : a journal of the British Diabetic Association.
[37] S. Newman,et al. Aerosol deposition considerations in inhalation therapy. , 1985, Chest.
[38] Günter Oberdörster,et al. Estimation of the Deposition of Aerosolized Drugs in the Human Respiratory Tract Due to Hygroscopic Growth , 1989 .
[39] B. Karlberg,et al. Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes. , 1996, Scandinavian journal of clinical and laboratory investigation.
[40] M. Newhouse,et al. Aerosol penetrance: a sensitive index of peripheral airways obstruction. , 1976, Journal of applied physiology.
[41] Effros Rm,et al. Measurements of pulmonary epithelial permeability in vivo. , 1983, The American review of respiratory disease.
[42] R. V. Lourenço,et al. Clinical aerosols. I. Characterization of aerosols and their diagnostic uses. , 1982, Archives of internal medicine.
[43] R. Upton,et al. KINETIC ASPECTS OF DRUG DISPOSITION IN THE LUNGS , 1999, Clinical and experimental pharmacology & physiology.
[44] A. Sant'annaGandra. Aerosols in medicine , 1957 .
[45] M. Hashida,et al. Improvement of the Pulmonary Absorption of (Asu1,7)-Eel Calcitonin by Various Protease Inhibitors in Rats , 1994, Pharmaceutical Research.
[46] T. Martonen. Mathematical model for the selective deposition of inhaled pharmaceuticals. , 1993, Journal of pharmaceutical sciences.
[47] G. Smaldone,et al. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. , 1987, The American review of respiratory disease.
[48] R. Baltimore,et al. Immunohistopathologic localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration. , 1989, The American review of respiratory disease.
[49] M. Matthay,et al. Clearance of different-sized proteins from the alveolar space in humans and rabbits. , 1992, Journal of applied physiology.
[50] Pieter Zanen,et al. The optimal particle size for β-adrenergic aerosols in mild asthmatics , 1994 .
[51] H. Folkesson,et al. Permeability of the respiratory tract to different-sized macromolecules after intratracheal instillation in young and adult rats. , 1990, Acta physiologica Scandinavica.
[52] A. Dobs,et al. Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulized insulin in patients with noninsulin-dependent diabetes mellitus. , 1998, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[53] J. Heyder,et al. Effect of cystic fibrosis on inhaled aerosol boluses. , 1989, The American review of respiratory disease.
[54] R. Djukanović,et al. Alveolar tissue inflammation in asthma. , 1996, American journal of respiratory and critical care medicine.
[55] H. Folkesson,et al. Alveolar epithelial clearance of protein. , 1996, Journal of applied physiology.
[56] A. Morice,et al. Pulmonary clearance of vasoactive intestinal peptide. , 1986, Thorax.
[57] J. Heyder. Particle transport onto human airway surfaces. , 1982, European journal of respiratory diseases. Supplement.
[58] P. Barnes,et al. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. , 1985, The American review of respiratory disease.
[59] J. Patton,et al. Mechanisms of macromolecule absorption by the lungs , 1996 .
[60] R. Schleimer. Uptake, Retention, and Biotransformation of Corticosteroids in the Lung and Airways , 2001 .